Nationwide Children's Hospital

Nationwide Children's Hospital is a leading pediatric health care and research center in the United States, providing care for over one million patients annually. With 68 facilities across Ohio and beyond, the hospital offers a wide range of treatments, including specialized care in cardiology, oncology, gastroenterology, and neonatology. It is dedicated to serving all children, regardless of their family's financial situation, ensuring that quality health care is accessible to everyone. Families often travel from various regions, seeking advanced and often life-saving treatments that are not available elsewhere. Through its commitment to pediatric expertise and innovative research, Nationwide Children's Hospital aims to improve the health and well-being of children now and in the future.

Luke Brown

Chief Financial and Administrative Officer and Executive Vice President

Chet Kaczor

Senior Vice President, Operations

Timothy Robinson

CEO

3 past transactions

Alcyone Therapeutics

Corporate Round in 2025
Alcyone Therapeutics is focused on advancing precision genetic therapies for central nervous system (CNS) disorders. The company develops innovative neural intervention technology aimed at addressing neurological conditions through targeted drug therapies. By integrating micro-fabrication technologies with advanced biomedical engineering, Alcyone Therapeutics seeks to enhance treatment options for patients suffering from chronic neuropathological conditions, including hydrocephalus. Their work aims to unlock new possibilities in CNS therapy development, addressing the unique challenges associated with treating these complex disorders.

Clarametyx Biosciences

Series A in 2024
Clarametyx Biosciences, Inc. is a biotechnology company founded in 2020 and headquartered in Columbus, Ohio. The company focuses on developing targeted and immune-enabling biologic therapies that address persistent infections associated with biofilms, which are protective layers that shield bacteria and complicate treatment. Clarametyx has created a novel technology platform that allows for the targeting of these biofilms, thereby enhancing immune response and facilitating antibiotic intervention. One of its key products in development is CMTX-001, a humanized monoclonal antibody currently in the late preclinical stage, aimed at treating hospital-acquired pneumonia. Clarametyx Biosciences is dedicated to combating life-threatening infections and reducing antibiotic resistance through its innovative therapeutic solutions.

STAQ Pharma

Series C in 2022
STAQ Pharma, Inc. is a Denver-based company that specializes in the manufacture and sale of compounded pharmaceutical medications. Initially known as QualMed Pharmacy, Inc., the company rebranded in 2018 and operates a cGMP-compliant outsourcing facility. STAQ Pharma produces a wide range of compounded medications, including non-sterile and sterile solutions, as well as repackaged sterile medications in prefilled syringes for hospital procedures. The company emphasizes safety, quality, and transparency in its operations, utilizing inventory systems to forecast demand and ensure timely availability of critical products for healthcare facilities. STAQ Pharma aims to enhance access to high-quality compounded medications through its online store and in-house production capabilities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.